PERCHERON THERAPEUTICS LIMITED — Director's Dealing 2003

Dec 23, 2003

24 December 2003

The Companies Section The Australian Stock Exchange Limited 530 Collins Street MELBOURNE VIC 3000

Dear Sir/Madam

Appendix 3Y - Change of Director's Interest Notice

Please find enclosed a Change of Director's Interest Notice for Robert W Moses.

Yours sincerely

Natalie Korchev Company Secretary

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity:	Antisense Therapeutics Limited
ABN:	41 095 060 745

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Robert W Moses
Date of last notice	14 October 2003

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest.	Mrs Lorraine Sandra Moses, wife of RobertMoses, non-executive chairman of AntisenseTherapeutics Limited, purchased ordinaryshares in Antisense Therapeutics Limited.
Date of change	22 December 2003
No. of securities held prior to change	288,462ordinary shares fully paid125,000options expiring 1/2/07exercisable at 20 cents each250,000options expiring31/7/05 exercisable at 20 centseach
Class	Fully paid ordinary shares
Number acquired	100,000
Number disposed
Value/ConsiderationNote: If consideration is non-cash, provide details and estimatedvaluation	$$13,000$ (i.e. 13 cents per share)

+ See chapter 19 for defined terms.

No. of securities held after change	388,462	ordinary shares fully paid
	125,000	options expiring 1/2/07
		exercisable at 20 cents each
	250,000	options expiring
		$31/7/05$ exercisable at 20 cents
		each
Nature of change	On-market trade
Example: on-market trade, off-market trade, exercise of options, issue ofsecurities under dividend reinvestment plan, participation in buy-back

Part 2 - Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder(if issued securities)	N/A
Date of change	N/A
No. and class of securities towhich interest related prior tochangeNote: Details are only required for a contract in relationto which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, provide details andan estimated valuation	N/A
Interest after change	N/A

$+$ See chapter 19 for defined terms.